Table 1 The general characteristic of the included studies
Author and year | No of patients (SNB:LIA) | Gender male/female | Age (mean, SNB:LIA) | Anesthesia | Surgery method | FNB | The drug and doses of SNB | The drug and doses of LIA | Concomitant pain management |
|---|---|---|---|---|---|---|---|---|---|
Mahadevan, D 2012 | 26/26 | 23/29 | 67.2/67.5 | General anesthesia | Standard medial parapatellar | 20 mL of 0.375% levobupivacaine | 20 mL of 0.375% levobupivacaine | 20 mL of 0.375% levobupivacaine | PCA for 48 h |
Safa, B 2014 | 33/32 | 32/33 | 61.2/60.7 | Spinal anesthesia | NS | 20 mL of 0.5% ropivacaine | 20 mL of 0.5% ropivacaine | 50 mL of 0.2% ropivacaine | PCA for 48 h |
Tanikawa, H 2014 | 23/23 | 7/39 | 72/71 | General anesthesia | Standard mid-vastus approach | 20 ml of 0.375% ropivacaine | 20 ml of 0.375% ropivacaine | 200 mg of ropivacaine and 0.5 ml of adrenaline | 0.2% ropivacaine infusion |
Gi, E 2014 | 24/25 | 4/45 | 78/77 | General anesthesia | NS | 20 ml 0.375% ropivacaine | 20 ml 0.375% ropivacaine | 60 ml 0.5% ropivacaine with 0.3 mg epinephrine | 60 mg oral loxoprofen sodium every 8 h |
Nagafuchi, M 2015 | 17/16 | 5/28 | 72/73 | General anesthesia | Midvastus approach | 20 mL of 0.375% ropivacaine | 20 mL of 0.375% ropivacaine | 100 mL of 0.2% ropivacaine by adding 0.5 mL of adrenaline | Continuous femoral block of 0.2% ropivacaine |
Uesugi, K 2014 | 105/105 | 41/159 | 76.3/76 | Spinal anesthesia | Themid-vastus approach | 20 mL of 0.75% ropivacaine | 10 mL of 0.75% ropivacaine | 20 ml of 0.75% ropivacaine, physiological saline 20 mL, adrenaline 0.3 mg, morphine hydrochloride and dexamethasone 3.3 mg | NS |
Spangehl, M. J 2015 | 79/81 | 71/89 | 67.8/67.7 | General anesthesia | Medial parapatellar approach | 30 mL 0.5% ropivacaine | 30 mL 0.5% ropivacaine | Ropivacaine Epinephrine Ketorolac Morphine sulfate | Analgesic medications |